紫杉醇和奈达铂诱导化疗联合同期放化疗治疗晚期鼻咽癌的疗效观察  

Paclitaxel plus nedaplatin induction chemotherapy concurrent radiotherapy in advanced nasopharyngeal carcinoma

作　　者：李素芳[1] 唐爽[1] 林灿洁 钟声学[1] 文小芝 

机构地区：[1]广西科技大学第二附属医院放射治疗科,柳州545006

出　　处：《中国肿瘤临床与康复》2014年第4期433-435,共3页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：广西卫生厅自筹经费科研课题(Z2013146)

摘　　要：目的探讨紫杉醇和奈达铂诱导化疗联合同期放化疗治疗局部晚期鼻咽癌的临床疗效。方法 90例中晚期局部鼻咽癌患者随机均分为两组,对照组患者给予放疗加同期化疗方案,观察组患者给予紫杉醇加奈达铂诱导化疗方案,两组患者放疗均采用调强适形放射治疗(IMRT)方式。比较两组患者患者不良反应和1、2年生存率。结果两组患者主要不良反应差异无统计学意义(P>0.05),观察组1年和2年控制率和无远处转移率显著高于对照组,差异有统计学意义(P<0.05),两组患者1、2年生存率差异无统计学意义(P>0.05)。结论紫杉醇+奈达铂诱导化疗联合同期放化疗可有效提高晚期局部鼻咽癌患者的局部控制率及无远处转移率,其不良反应可耐受,值得临床推广。Objective To investigate clinical effect of nedaplatin plus paclitaxel combined concur- rent chemoradiotherapy in locally advanced nasopharyngeal carcinoma. Methods 90 cases with locally advanced nasopharyngeal carcinoma were randomly divided into the control group and observation group. The control group were treated with radiotherapy ＋ earlier chemotherapy, and the observation group nedaplatin ＋ paclitaxel combined with concurrent chemoradiotherapy. Both groups adopted intensity-modulated radiation therapy （IMRT）. Adverse reactions and survavial rates for 1 year and 2 years were compared. Results There was no difference in adverse reactions between the two groups （ P 〉 0. 05 ）. The 1-year and 2-year control rate and distant metastasis rate of the observation group were significantly higher than those of the control group （P 〈 0. 05 ）, and there were no significant differences in 1-year and 2-year survival rate between the two groups （P 〉 0. 05）. Conclusion Toxicity of nedaplatin ＋ paclitaxel combined IMRT in locally advanced nasopharyngeal carcinoma is endurable, and can effectively improve the local cotrol rate and distant metasta- sis rate, which is wrothy of further clinical application.

关 键 词：诱导化疗 同步放化疗 晚期局部鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]